In early August 2026, a major development sent shockwaves through the global pharmaceutical industry — British pharmaceutical giant AstraZeneca and U.S. pharmaceutical company Bristol Myers Squibb (BMS) were reported to be in discussions over a potential merger. If completed, the deal would create a pharmaceutical powerhouse with a market capitalization approaching US$400 billion, ranking among the world’s largest pharmaceutical companies and becoming one of the biggest M&A transactions in the history of the industry.

Following the news, AstraZeneca’s share price fell more than 8% in a single trading session, wiping out approximately US$22 billion in market value, while BMS shares rose nearly 6%. The contrasting market reactions reflected investors’ different expectations toward the potential transaction.

Although the proposed merger is focused on the human pharmaceutical sector, its impact could extend across the broader life sciences supply chain — including the veterinary API industry.

Why AstraZeneca and BMS Are Considering a “Strategic Marriage”

For AstraZeneca, the deal represents an opportunity to accelerate long-term growth.

In the first half of 2026, AstraZeneca reported revenue of US$30.672 billion, representing year-on-year growth of 6%. The company has set an ambitious target of achieving US$80 billion in annual revenue by 2030, compared with approximately US$58.7 billion in the previous year. Expanding its presence in the U.S. market remains a critical growth strategy, as the region already contributes around 42% of AstraZeneca’s total revenue.

For BMS, the pressure comes from an approaching patent cliff.

BMS generated revenue of US$24.462 billion in the first half of 2026, up 4% year on year. However, several of its key products, including the immunotherapy drug Opdivo and anticoagulant Eliquis, are expected to face patent expirations around 2028. The company is actively seeking new growth engines and exploring strategic alternatives.

The two companies also have significant overlap in oncology, with cancer-related products accounting for more than 40% of sales for both companies. While this creates potential synergies, it could also become the biggest challenge during antitrust reviews.

Four Potential Impacts on the Veterinary API Industry

1. API Procurement Structures May Be Reshaped

AstraZeneca and BMS together represent hundreds of billions of dollars in pharmaceutical activity and purchase substantial volumes of chemical raw materials, APIs, and CDMO services every year.

Following a potential merger, their procurement systems could be integrated, creating stronger purchasing power and greater supplier consolidation.

For the veterinary API industry, this development deserves attention because human pharmaceutical APIs and veterinary APIs share significant parts of the global supply chain. Many manufacturers simultaneously supply both human and animal pharmaceutical companies.

If the merged company restructures its supplier network, companies supplying both human and veterinary APIs may face:

• supplier reassessment;
• order redistribution;
• increased pricing pressure;
• stricter qualification requirements.

Large pharmaceutical groups may increasingly favor suppliers with strong GMP systems, international registrations, stable capacity, and integrated manufacturing capabilities.

2. Antitrust Reviews Could Create Acquisition Opportunities

The biggest obstacle facing the potential merger is regulatory approval.

Because AstraZeneca and BMS compete directly in oncology and other therapeutic areas, regulators may require significant asset divestitures before approving the transaction.

A similar situation occurred in 2019 when BMS acquired Celgene. U.S. regulators required the divestiture of Celgene’s psoriasis drug Otezla, which was valued at approximately US$13.4 billion.

For the veterinary pharmaceutical sector, forced divestitures could create opportunities.

Historically, multinational pharmaceutical companies have adjusted their animal health strategies through major transactions:

• Novartis sold its animal health business to Eli Lilly for approximately US$5.4 billion;
• Pfizer separated its animal health division into Zoetis, now one of the world’s largest animal health companies.

If AstraZeneca or BMS decides to divest non-core assets, companies looking to expand in animal health could find attractive acquisition opportunities.

3. Supply Chain Concentration Risks May Increase

A larger pharmaceutical group would have stronger influence over CDMOs, specialty chemical suppliers, and API manufacturers.

As procurement becomes increasingly centralized, large suppliers with global compliance capabilities may benefit, while smaller manufacturers could face greater pressure.

For veterinary API companies, this trend may accelerate existing industry changes:

• human pharmaceutical companies expanding into veterinary markets;
• veterinary pharmaceutical companies integrating upstream into API production;
• consolidation among raw material manufacturers.

Companies unable to enter the supply chains of major pharmaceutical groups may increasingly shift toward niche markets such as:

• veterinary APIs;
• feed additives;
• specialty animal health products.

This could further intensify competition in the veterinary raw material sector.

4. M&A Trend Provides a Warning Signal for Veterinary Companies

Regardless of whether the AstraZeneca–BMS transaction is ultimately completed, the potential deal sends a clear message: global pharmaceutical companies are entering a new era of consolidation.

The global animal health market is also expanding rapidly, with the veterinary pharmaceutical market estimated at approximately US$48.5 billion in 2025 and expected to exceed US$65 billion by 2030.

As competition increases, mergers, acquisitions, strategic partnerships, and vertical integration are becoming increasingly important pathways for companies seeking sustainable growth.

The lesson for veterinary API manufacturers is clear:

Large pharmaceutical companies are using mergers to overcome patent expiration risks, strengthen pipelines, and expand markets. Veterinary pharmaceutical companies and API suppliers must also rethink their future strategies — because independent growth alone may become increasingly challenging in a more concentrated global market.

Conclusion: A Signal of Change Across the Global Pharmaceutical Supply Chain

The AstraZeneca–BMS merger discussion remains at an early stage, and the transaction could still face delays or fail due to regulatory challenges.

However, regardless of the final outcome, the potential US$400 billion pharmaceutical merger highlights a broader industry transformation.

As global pharmaceutical giants reshape their competitive landscape, every part of the supply chain — including veterinary APIs — will inevitably feel the impact.

For companies in the veterinary raw material sector, the key question is no longer:

“Does this merger affect us?”

The more important question is:

“When the global pharmaceutical tide rises, will we be pushed aside, or will we have the capability to ride the wave?”